Heparin-coated cardiopulmonary bypass circuits: current status

Hsu, L-C.
September 2001
Perfusion;Sep2001, Vol. 16 Issue 5, p417
Academic Journal
Heparin-coated circuits have been subjected to vigorous testing, both experimentally and clinically, for the past decade. When the functions of heparin are preserved on the surface, the heparinized surface plays multiple roles in attenuating the systemic inflammatory response. These include the ability to attenuate contact activation, coagulation activation, complement activation and, directly or indirectly, platelet and leukocyte activation. The heparinized surface also renders the cardiopulmonary bypass (CPB) circuits hydrophilic and protein resistant and augments lipoprotein binding. The multifunctional nature of the heparinized surface contributes to the overall biocompatibility of the surface. Clinically, heparin-coated circuits become most effective in reducing systemic inflammatory response and in improving morbidity, mortality, and other patient outcome related parameters when material-independent blood activation is controlled or minimized through a global biocompatibility strategy. Techniques involved in the global biocompatibility strategy are readily available and are being effectively and safely practiced at several centers. With the global biocompatibility strategy, outstanding and reproducible results have been routinely achieved with conventional CPB techniques. Alternative revascularization procedures should equal or surpass conventional CPB, using best clinically proven strategies with respect to patient outcome and long-term graft patency.


Related Articles

  • Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass. Gruenwald, C.; de Souza, V.; Chan, A.; Andrew, M. // Perfusion;Jun2000, Vol. 15 Issue 3, p203 

    This study was designed to test the validity of whole blood heparin concentration (WHBC) measurements using an on-site protamine titration assay with the Hepcon instrument (Medtronic Blood Management, Parker, CO, USA) in pediatric patients less than 1 year old undergoing cardiopulmonary bypass...

  • Editorial. Kurusz, M. // Perfusion;May2008, Vol. 23 Issue 3, p145 

    The article discusses various reports published within the issue, including one by Puri and colleagues on a new monitoring tool for cerebral venous congestion during cardiopulmonary bypass and another by Kordis and colleagues on the benefit of a heparin-coated minimized extracorporeal circuit.

  • Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction. Flom-Halvorsen, Hanne I; Øvrum, E; Brosstad, F; Tangen, G; Ringdal, MAL; Øystese, R // Perfusion;Sep2002, Vol. 17 Issue 5, p339 

    Objective: The two most commonly used heparin-coated systems for cardiopulmonary bypass (CPB) are the Carmeda Bio-Active Surface (CBAS) (Medtronic, Minneapolis, MN, USA) and the Duraflo II coating (Baxter Healthcare, Irvine, CA, USA). The two surfaces are technically unequal and previous...

  • The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress. Sohn, N.; Marcoux, J.; Mycyk, T.; Krahn, J.; Meng, QH; Gourlay, T.; Shedden, Laurie // Perfusion;Nov2010, Vol. 25 Issue 6, p427 

    A letter to the editor is presented in response to the article "The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress," by N. Sohn and colleagues in the previous issue.

  • Reply to Letter. Sohn, N.; Marcoux, J.; Mycyk, T.; Krahn, J.; Meng, Q. H. // Perfusion;Nov2010, Vol. 25 Issue 6, p429 

    A response by N. Sohn and colleagues to a letter to the editor on their article "The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress," in the 2009 issue is presented.

  • Hereditary and Acquired Antithrombin Deficiency: Epidemiology, Pathogenesis and Treatment Options. Maclean, Peter S.; Tait, R. Campbell // Drugs;2007, Vol. 67 Issue 10, p1429 

    Antithrombin is a glycoprotein critical to the regulation of coagulation. Its primary action is the inhibition of the activated coagulation factors IIa (thrombin) and Xa. In addition there is growing evidence to suggest that antithrombin also plays a role in the inhibition of inflammation...

  • Leukodepletion and aprotinin improve clinical outcome after extracorporeal circulation. Gott, J. // Perfusion;Mar2001 Supplement 1, Vol. 16, p5 

    Most cardiac operations involve the use of extracorporeal circulation with its attendant systemic inflammatory response syndrome. Many anti-inflammatory strategies hold promise for reducing the associated morbidity of cardiopulmonary bypass. The application of pharmacological and mechanical...

  • Biomaterial development for cardiopulmonary bypass. Gourlay, T. // Perfusion;Sep2001, Vol. 16 Issue 5, p381 

    Cardiopulmonary bypass (CPB) is dependent on materials foreign to the patient for its successful application. When blood comes into contact with these so-called biomaterials, an inappropriate inflammatory response, which can be life-threatening in some patients, may develop. The reason for this...

  • HEMOSTATIC DEFECTS INDUCED BY CARDIOPULMONARY BYPASS. Bick, Rodger L.; Arbegast, Neil; Crawford, Leah; Holterman, Margaret; Adams, Thompson; Schmalhorst, William // Vascular Surgery;Sep/Oct1975, Vol. 9 Issue 4, p228 

    Discusses studies on a hemorrhagic syndrome associated with a cardiopulmonary bypass (CPB). Causes of the post-CPB hemorrhagic syndrome, including inadequate heparin neutralization; Results of an evaluation of the hemostatic defects induced by CPB; Implications of the presence of fibrinolytic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics